Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study - Takeaways - MDSpire

Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study

  • By

  • Mengwei Feng

  • Yunjie Wu

  • Chaoqing Xie

  • Jingxian Xing

  • Deguang Wang

  • Xue Liang

  • Juan Liu

  • Hui Gao

  • Tao Geng

  • July 15, 2026

Share

  • 1

    Coronary artery ectasia (CAE) is linked to thrombotic complications due to abnormal dilation and slow blood flow.

  • 2

    In a study of 312 CAE patients, low-dose rivaroxaban combined with antiplatelet therapy significantly reduced major adverse cardiovascular events.

  • 3

    After 36 months, the combination therapy showed an 8.1% MACE rate compared to 21.8% for antiplatelet therapy alone.

  • 4

    Improvements in biomarkers were greater in the combination therapy group, with no significant difference in bleeding rates.

  • 5

    A predictive model based on D-dimer and Markis classification was developed but requires external validation.

Original Source(s)

Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study

  • by Mengwei Feng, Yunjie Wu, Chaoqing Xie, Jingxian Xing, Deguang Wang, Xue Liang, Juan Liu, Hui Gao, Tao Geng

  • July 15, 2026

Related Content

Factors Influencing Weight Gain at Different Stages of the Fontan Pathway for Children with Functionally Single Ventricle Heart Disease

Association of plasma homocysteine with the atherogenic index of plasma and modification by body mass index: a cross-sectional study

Stroke Audit Finds Long CT-to-CTA Times

A regional UK audit found wide variation in imaging intervals among patients referred for mechanical thrombectomy and identified potentially modifiable barriers to timely vascular imaging.